The pharmacokinetic and pharmacodynamic properties of biphasic insulin Aspart 70 (BIAsp 70) are significantly different from those of biphasic insulin Aspart 30 (BIAsp 30)

What Was Tested

This randomized controlled trial paper looks at Insulin Aspart.

Who Took Part

The study group was 27 patients.

By PubMed's age tags, the people studied were adults, both men and women.

In this randomised, double-blind, two-period crossover trial, 27 patients with type 1 diabetes received 7 days of treatment with BIAsp 30 three times daily (TID) and 7 days of treatment with BIAsp 70 TID, with a 2 - 6 week washout period between treatment periods.

How the Study Was Run

The researchers set it up as a randomized, double-blind and crossover study.

The patients were allocated by chance, so the Insulin Aspart group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Insulin Aspart, so expectations could not easily colour the readings.

In the crossover set-up each of the patients took both Insulin Aspart and the comparison in turn, acting as their own control.

What Was Measured

Topics PubMed links to this paper include Diabetes Mellitus, Type 1, Glucose Clamp Technique and Insulin.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Aspart in 27 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2005 (Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association), a journal based in Germany.

More context: the Insulin Aspart compound page.